pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,695 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT811Endpoints609BioPharma Dive235onclive165Fierce Biotech79BioSpace78raps32globenewswire health24fda recalls
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Is the military fueling eating disorders?
    A brief hantavirus update, some good news about death, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
    Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...
    Endpoints · 1mo ago↗ source
  • Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
    A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow.
    STAT · 1mo ago↗ source
← prev
page 38 of 68
next →
20
fda press20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Opinion: The medical-billing AI arms race between providers and insurance
    “The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.
    STAT · 1mo ago↗ source
  • Opinion: The Amish way of health care
    “Public health is going to have to talk about the Amish more and more”: Listen to STAT’s "First Opinion Podcast" on the Amish and health care.
    STAT · 1mo ago↗ source
  • Opinion: How the military may be fueling eating disorders in men
    “Much of the rhetoric, imagery, and policy messaging from the Trump administration centers on extreme masculine ideals,” First Opinion author writes.
    STAT · 1mo ago↗ source
  • STAT+: NIH cuts weakened network primed to respond to outbreaks like Ebola
    While NIH-funded centers weren’t on the front lines of virus responses like the CDC or USAID, some researchers involved in the network said the cuts have damaged relationships with experts…
    STAT · 1mo ago↗ source
  • STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
    Advocates were already dreading Medicaid's work requirements. New rules are worse than they feared.
    STAT · 1mo ago↗ source
  • Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.
    A senior NIH scientist and his research fellow were charged with smuggling vials of deactivated mpox virus into the country from Africa and lying about it.
    STAT · 1mo ago↗ source
  • Lilly gives hospitals deadline to comply with 340B claims data policy
    Eli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push to…
    Endpoints · 1mo ago↗ source
  • FDA details flexibilities for new cell and gene therapies to leverage past data
    The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…
    Endpoints · 1mo ago↗ source
  • Anti-aging biotech NewLimit raises $435M at $3B+ valuation
    The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said Tues…
    Endpoints · 1mo ago↗ source
  • STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
    Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
    STAT · 1mo ago↗ source
  • What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
    CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...
    Endpoints · 1mo ago↗ source
  • STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
    Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Male contraception startup closes $92.5M Series B; Novartis bets on actinium
    💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily treatment is a gel rubbed on the shoul…
    Endpoints · 1mo ago↗ source
  • Travere pays Everest $112M upfront to grow rare kidney disease pipeline
    Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…
    Endpoints · 1mo ago↗ source
  • Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
    Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initia…
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
    Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks
    STAT · 1mo ago↗ source
  • How one state’s medical meal program lowered health care costs
    Medicaid work requirements, fast-tracked funding for experimental Ebola vaccines, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout
    Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Executi…
    Endpoints · 1mo ago↗ source
  • Citing 'dangerous deals,' lawmakers propose China restrictions
    A bipartisan group of Michigan lawmakers released a new bill that could greatly stifle the booming cross-border deals spree between Chinese and American biotechs. Rep. John Moolenaar (R-MI) and Rep…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Roche details narrow failure of breast cancer pill trial
    Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a pivotal Phase 3 trial. Data presented Tuesday at ASCO reveal ...
    Endpoints · 1mo ago↗ source
  • Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
    Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registrationa…
    Endpoints · 1mo ago↗ source
  • Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
    Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But…
    Endpoints · 1mo ago↗ source